Inhaled corticosteroids and risk of lower respiratory tract infection withMoraxella catarrhalisin patients with chronic obstructive pulmonary disease

Abstract

BackgroundUse of inhaled corticosteroids (ICS) is common in patients with chronic obstructive pulmonary disease (COPD) and has been associated with an increased risk of pneumonia.Moraxella catarrhalisis one of the most common bacterial causes of infectious exacerbation in COPD. Currently, to our knowledge, no studies have investigated if ICS increases the risk of lower respiratory tract infection withM. catarrhalisin patients with COPD.ObjectiveTo investigate if accumulated ICS use in patients with COPD, is associated with a dose-dependent risk of infection withM. catarrhalis.MethodsThis observational cohort study included 18 870 persons with COPD who were registered in The Danish Register of COPD. Linkage to several nationwide registries was performed.Exposure to ICS was determined by identifying all prescriptions for ICS, redeemed within 365 days prior to study entry. Main outcome was a lower respiratory tract sample positive forM. catarrhalis. For the main analysis, a Cox multivariate regression model was used.We defined clinical infection as admission to hospital and/or a redeemed prescription for a relevant antibiotic, within 7 days prior to 14 days after the sample was obtained.ResultsWe found an increased, dose-dependent, risk of a lower respiratory tract sample withM. catarrhalisamong patients who used ICS, compared with non-users. For low and moderate doses of ICS HR was 1.65 (95% CI 1.19 to 2.30, p=0.003) and 1.82 (95% CI 1.32 to 2.51, p=0.0002), respectively. In the group of patients with highest ICS exposure, the HR ofM. catarrhaliswas 2.80 (95% CI 2.06 to 3.82, p<0.0001). Results remained stable in sensitivity analyses. 87% of patients fulfilled the criteria for clinical infection, and results remained unchanged in this population.ConclusionOur study shows a dose-dependent increased risk of infection withM. catarrhalisassociated to ICS exposure.